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INTRODUCTION
Croton oil and its active ingredients, phorbol
esters, are powerful irritants and tumor-promoting
agents (1, 2) . The most active is the 12-0-tetra-
decanoate and 13-acetate ester of the 20-carbon
alcohol phorbol (Fig. 1). We investigated the
effect of this phorbol ester on human blood
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ABSTRACT
The phorbol ester 12-0-tetradecanoyl-phorbol-13-acetate, a potent tumor-promoting
agent, caused irreversible platelet aggregation when more than 0 .02µM was stirred with
human citrated or heparinized platelet-rich plasma (PRP) . With washed platelets, 1 nM
was effective. The alcohol phorbol, which has little tumor-promoting activity, failed to
cause platelet aggregation . With all but low concentrations of phorbol ester, aggregation
was succeeded by a rapid phase. The latter was prevented or reduced by enzymes which
destroy ADP and by aspirin, was associated with a change in platelet shape, and was pre-
sumably due to released ADP . At higher concentrations, only a rapid phase was seen, and
these inhibitors were not effective. Low concentrations did not aggregate platelets in PRP
containing sufficient EDTA or EGTA to chelate ionized calcium or in PRP from thromb-
asthenic patients; higher concentrations caused slight aggregation . Both the primary,
non-ADP-dependent aggregation and the rapid ADP-dependent aggregation were mark-
edly inhibited by substances which increase cyclic AMP, metabolic inhibitors, and the
sulfhydryl inhibitor N-ethylmaleimide . Phorbol ester reduced platelet cyclic AMP only
when it had been previously elevated by prostaglandin El . 1µM did not release $-glu-
curonidase, lactic dehydrogenase, or inflammatory material from platelets in 4-5 min
despite marked aggregation, but liberated all three in 30 min. The possibility is discussed
that low phorbol ester concentrations cause primary aggregation by a direct action on
platelet actomyosin.
platelets because it is structurally similar to prosta-
glandins, and found it to be an extremely potent
aggregating agent.
Platelet aggregates form the major constituents
of hemostatic plugs and arterial thrombi, and
are also important in the genesis of venous
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CH2OH sodium EDTA was added to labeled citrated PRP,
the mixture was chilled and the platelets were washed
as described by Cronberg and Caen (16).
H,
FIGURE 1 The structure of phorbol ester.
thrombi. In vivo, thrombin and contact of plate-
lets with collagen and basement membrane prob-
ably serve as the physiologic stimuli for aggrega-
tion. In vitro, aggregation is induced when these
agents or low concentrations of ADP or epi-
nephrine are added to stirred platelet-rich plasma
(PRP), a reagent prepared by slowly centrifug-
ing blood anticoagulated with sodium citrate or
heparin (3, 4, 5). ADP is considered a primary
stimulus to aggregation, and ADP released from
platelets is at least partly responsible for the aggre-
gation induced by thrombin, collagen, and epi-
nephrine. These agents induce a release reaction
akin to secretion in which ADP, ATP, and seroto-
nin (or ["C]serotonin if the platelets have been
tagged with this substance) are rapidly liberated
from granules (6, 7) . The mechanism of ADP-
induced aggregation is poorly understood al-
though use of inhibitors has provided clues (8, 9,
10). Platelet actomyosin and an ecto-ATPase
have been implicated (11, 12, 13). The present
investigation was undertaken to characterize
aggregation induced by phorbol ester and to
compare it with that induced by ADP.
MATERIALS AND METHODS
Preparation of Platelets
Venous blood from normal donors who had taken
no aspirin for a week was usually collected into 0 .1
vol of 3.2% (0.109 M) sodium citrate . PRP which
had contacted only plastic surfaces was prepared by
room temperature centrifugation at 300 g for 8-10
min, and incubated with [14C]serotonin as previously
described (14, 15) . PRP was occasionally prepared
from blood containing 4 U heparin/ml or 3 mM
EGTA. Citrated PRP was also obtained from two
patients with thrombasthenia (studied through the
kindness of Dr. Harvey Weiss, Roosevelt Hospital,
New York City) or from patients with typical severe
von Willebrand's disease.
Some experiments were carried out with washed
platelets. After %5th vol of 135 mM neutralized
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Measurement of Aggregation and Release
Aggregation was studied in glass test tubes or
cuvettes by incubating 8 vol (usually 0 .32 ml) of
PRP with 1 vol of inhibitor or its diluent and then
adding I vol of aggregating agent or a control solu-
tion. The figures in the text are the final concentra-
tions of inhibitors and aggregating agents . The
samples were either stirred in an aggregometer
(Chrono-log Corp., Broomall, Pa., or Payton Asso-
ciates, Inc., Buffalo, N. Y.) which measures light trans-
mission of PRP, or shaken in a reciprocating water
bath at 37ßC. At intervals, they were chilled and
centrifuged, and the plasma retained for measure-
ment of [t4C]serotonin or enzymes. Radioactivity
was measured as previously described (14, 15), lactic
dehydrogenase was assayed with a kit from Boehrin-
ger Mannheim Corp., New York, and (3-glucuroni-
dase was measured by a slight modification of the
method of Talalay et a] . (17) in which about 270
nmol of phenolphthalein glucuronide (Sigma Chem-
ical Co., St. Louis, Mo.) was hydrolyzed per ml
frozen and thawed PRP in 18 h. To measure release
of ADP and ATP, EDTA (final concentration of
5.4 mM) was added to the aggregometer cuvette
at the desired time. The PRP was chilled and cen-
trifuged for 10 min at 12,000 g in the cold. After
precipitating the plasma proteins with an equal vol-
ume of 95% ethanol, ADP and ATP were assayed
by the firefly luminescence method (18) . Cyclic
AMP was measured by radioimmunoassay (19)
(reagents from Collaborative Research, Waltham,
Mass.) on extracts of PRP prepared by adding an
equal volume of 12% trichloroacetic acid .
Inflammatory activity of platelet preparations
was estimated in rabbits. 1 nil of 5% Evans blue
dye was injected intravenously, followed by the
intradermal injection of 0.1 ml of the preparations
in the depilated abdomen (20) . 1 h later, the size
of the blue spot was estimated visually.
Morphology
PRP was added to formalin fixative and the plate-
lets were examined by phase-contrast microscopy
(21).
ADP Destruction
ADP was usually removed from citrated PRP by
adding either creatine phosphate (CP) (Grade A,
disodium salt, Calbiochem, La Jolla, Calif.) plus
creatinephosphokinase (CPK) (Sigma Chemical
Co., 105 U/mg protein) at final concentrations per
milliliter of 2.5 µmol and 50 U, respectively (22),or apyrase (Grade 1, Sigma Chemical Co ., 2.4 U
ATPase and 2.9 U ADPase/mg protein) at a final
concentration of 2 mg/ml .
Reagents
The phorbol ester and the alcohol phorbol were
obtained from Consolidated Midland Corp ., Brew-
ster, N. Y. Several experiments were carried out with
phorbol ester prepared by Dr. A. Sivak, Department
of Environmental Medicine, New York University,
with identical results . A 16 mM solution in DMSO
retained full activity for at least a year at 4ßC.
Before use, it was diluted to 1 .0 mM with DMSO
and further diluted with isotonic saline . ADP (so-
dium salt, Sigma Chemical Co.) was kept frozen in
isotonic saline at 1 mM. A maximum of 1 µl of 95%
ethanol, or 2 µl of DMSO was added to 0.4 ml PRP
samples since higher concentrations inhibited aggre-
gation and release . Prostaglandins El, E2, F1 and
F2ß (Upjohn Co., Kalamazoo, Mich. and Ono
Pharmaceuticals, Osaka, Japan) were dissolved in
95% ethanol at 0.5 mg/ml and kept at -20ßC.
Theophylline (Schwarz-Mann, Div. Becton, Dickin-
son and Co., Orangeburg, N. Y.) and the sodium salt
of N6, 2'-O-dibutyryl adenosine-3'5'-cyclic mono-
phosphate (dibutyryl cyclic AMP) (Calbiochem,
La Jolla, Calif.) were dissolved in saline. Ouabain
(injectable) was prepared by Eli Lilly and Co.,
Indianapolis, Ind. L-Tosylphenylalanine chloro-
methylketone (L-TPCK) and 1-L-chloro-2-tosyl-
amido-7-amino-2-heptanone (L-TLCK) were ob-
tained from Cyclo Chemical Corp., Los Angeles,
Calif. L-TLCK was freshly dissolved in isotonic
saline ; L-TPCK was dissolved in DMSO and kept
at 4ßC. Aspirin (Amend Drug Co., New York.)
was stored frozen at 1 mM in isotonic saline . Phen-
tolamine (Regitine) was manufactured by Ciba
Chemical Corp., Summit, N. J.
RESULTS
Aggregation Induced by Phorbol Ester
Phorbol ester aggregated platelets in citrated
or heparinized PRP at concentrations as low as
0.02 AM. The alcohol phorbol did not aggregate
platelets when tested in a concentration as high
as 80 µM. Phorbol ester did not aggregate erythro-
cytes; leukocytes were not tested.
The effect of various concentrations on the
pattern of aggregation depended on the ag-
gregometer used, possibly because stirring rates
were not accurately designated . At low concen-
trations, aggregation proceeded linearly with a
slope which varied with the concentration. At
about 10 min, aggregation usually ceased . How-
ever, disaggregation did not occur and the tracing
remained horizontal for at least 1 h. At interme-
diate concentrations, the initial slow aggregation
was followed by a rapid phase, giving a sigmoidal
type of tracing. At high concentrations, the rapid
phase occurred with little or no initial slow fall
in light transmission (Fig. 2 A) ; the slope varied
directly and the delay inversely with the tem-
perature (Fig. 2 B). In studies with our Chrono-
log aggregometer, linear curves characteristic
of low concentrations were observed with con-
centrations as high as 0.1 µM (Fig. 2 A), whereas
with our Payton instrument a sigmoidal curve
was almost always seen with 0.05 µM (Fig. 4) and
sometimes even with 0.03 µM (Fig. 5).
When divalent cations were chelated by adding
5.4 mM EDTA to PRP, 0.05 µM phorbol ester
had no visible effect and 0.5 µM caused only
very slight aggregation . EGTA caused similar
inhibition. Disaggregation occurred when EDTA
was added soon after phorbol ester ; with more
than 0.1 µM phorbol ester, aggregation was re-
sumed at a reduced rate (Fig. 3). When EDTA
was added later, aggregation was arrested. Plate-
lets in PRP from thrombasthenic patients re-
sponded like those in EDTA PRP ; only slight
aggregation occurred with relatively high concen-
trations of phorbol ester. The compound caused a
normal response in PRP from patients with
von Willebrand's disease . Aggregation with a
low concentration of ADP was enhanced when
it was added soon after the start of aggregation
caused by a low concentration of phorbol ester.
Release Induced by Phorbol Ester
To determine whether released ADP was re-
sponsible for phorbol ester-induced aggregation,
tests were carried out in the presence of enzymes
which destroy this nucleotide. Apyrase or CP
plus CPK had no effect on the slow progressive
aggregation induced by low concentrations of
phorbol ester, prevented or diminished the rapid
second phase of aggregation produced by inter-
mediate concentrations, and had little effect
on aggregation caused by higher concentrations
(Fig. 4) . Doubling the concentration of CP and
quintupling that of CPK and apyrase did not
cause additional inhibition. This high concentra-
tion of apyrase prevented any aggregation with
50 µM ADP.
The concentrations of ATP, ADP, and ["C]
serotonin released into the plasma were measured
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FIGURE Q Aggregometer tracings of the response of human citrated PRP to (A) three concentrations of
phorbol ester tested at 37°C and (B) 1 µM phorbol ester tested at three different temperatures. The
abscissa represents light transmission units (LTU). PRP was set at 10 and platelet-poor plasma (PPP)
at 90 (Chrono-log aggregometer) .
4 5
FIGURE 3 Aggregometer tracings of the effect of EDTA on the response to 5 µM phorbol ester. Three
tracings are superimposed; in two of the tests, 20 µ1 of 0.135 M EDTA was added to 0.5 ml PRP (Chrono-
log aggregometer).FIGURE 4 Aggregometer tracings showing aggregation induced by four concentrations of phorbol eater
in the presence and absence of CP and its kinase (Payton aggregometer) .
10 min after aggregation was induced with phor-
bol ester (Table I). Nucleotides were not found
in the supernatant plasma when aggregation was
induced by 0.02 µM phorbol ester but were pres-
ent with 0.05 µM or more. Release of [14C]sero-
tonin was generally greater with the higher phor-
bol ester concentrations but marked aggregation
could occur with little release of radioactivity .
Enzymes which destroyed ADP usually decreased
[I'C]serotonin release even when they inhibited
aggregation only slightly. Release induced in 4
min by a high concentration of phorbol ester (1
µM) took place in the presence of EDTA or with
thrombasthenic PRP, whereas ADP-induced re-
lease was abolished (Table II) .
When release was assessed at intervals during
aggregation, it was found to occur mainly during
the latter part of the steep phase of aggregation
(Fig. 5) . When PRP was stirred with 1 µM phor-
bol ester, aggregation was complete within 5 min,
but radioactivity continued to be liberated from
[I'C]serotonin-labeled platelets until almost all
of the label had been released in 2 h (Fig. 6).
Platelet ß-glucuronidase and lactic dehydrogenase
had not been released at 4 min but by 2 h about
25% and 95%, respectively, of these enzymes
were found in the supernatant plasma. When 1
µM phorbol ester was incubated with PRP with-
out stirring, no aggregation occurred, and a much
lower percentage of radioactivity or enzymes
was released in 2 h. Phorbol ester added to un-
stirred PRP immediately before freezing had no
effect on the ß-glucuronidase activity of frozen
and thawed PRP but decreased its lactic dehy-
drogenase activity by 10-16%.
Platelet Shape Change
Platelets did not change from disks to spiny
spheres when aggregation was induced by very
low concentrations of phorbol ester or by some-
what higher concentrations (e .g., 0.05 µM) in
the presence of CP plus CPK. When ADP was
not removed enzymatically, phorbol ester induced
a change in platelet shape with all but the lowest
concentrations. Shape change but not aggregation
occurred when 1 µM phorbol ester was added to
EDTA or thrombasthenic PRP .
Effect of Inhibitors on Phorbol Ester-Induced
Aggregation and Release
Table III illustrates the effect of various in-
hibitors of aggregation. They were tested on PRP
shaken in a water bath at 37°C with ADP or rela-
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Aggregation and Release of [14C]Serotonin, ADP, and A TP Induced by Phorbol Ester with and without Enzymes
which Destroy ADP
* Change in light transmission units as percent of difference in light transmission of PRP and PPP in
10 min.
$ Columns headed Enz. indicate results in the presence of CP plus CPK (Exps . 1 C-8 C) or apyrase (Exps.
1 A-9 A) . Experiments with the same number were carried out on the same PRP.
§ ADP plus ATP.
TABLE II
Release of [14C]Serotonin in ED TA-Treated and Thrombasthenic PRP after 4 Min Shaking with Phorbol Ester
or ADP
tively high concentrations of phorbol ester . Aggre-
gation observed at 4 min was 4 + without inhibi-
tors. The inhibitors had similar effects on aggre-
gation induced by the two agents but were more
active against ADP. Ouabain (0.1, 1.0, or 10 µM
incubated for 120 min at room temperature or for
15 min at 37°C) did not inhibit phorbol ester-
induced aggregation.
Concentration of phorbol ester
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When the level of cyclic AMP in platelets was
increased by incubating the PRP with prosta-
glandin E 1 (PGE 1), stirring the samples with I
µM phorbol ester for 3 min reduced the level of
cyclic AMP in a dose-dependent manner. The
ester had no effect without PGE 1 (Table IV) .
To assess the effect of inhibitors on the initial
phase of aggregation, studies were carried out in
0.02 MM 0.05 MM 0.1-0.5 µM
Expt.
Aggrega
tion*
Release of:
tion*
Release of:
tion*
Release of:
14C ADP ATP 14C ADP ATP 14C ADP ATP
(Enzt) (Enzt) (Enzt) (Enzt) (Enzt) (Enz$)
% % % % µM M % % % % AM AM % % % % MM hM
1 C 42 21 0 0 0 0 62 59 28 16 1 .6 0 .5
2 C 74 38 19 11 1 .8 1 .1
3 C 13 11 5 0 0 0 77 45 33 0 3.9 0.4 70 66 28 13 12 .1 1 .3
4 C 13 7 0 0 0 0 57 38 2 1 0.6 0.4 85 75 7 8 2 .6 1 .4
5 C 75 67 2 0 - -
6 C 11 8 10 4 - - 44 24 10 4 - -
7 C 66 66 0 0 - -
8 C 74 66 22 14 - -
1 A 35 23 0 0 0 0 72 68 14 35 2 .4§
5 A 75 55 2 2 - -
8 A 74 75 22 18 - -
9 A 59 4 15 0 - - 50 24 6 0 - -
Phorbol ester (I MM) ADP (10 AM)
Condition of PRP
Aggregation 14C in supernatant Aggregation 14C in supernatant
Citrated normal 4+ 12 4+ 25
Citrated normal with 5.4 mM
EDTA
f 11 0 0
Citrated thrombasthenic f 12 0 0100
o w
â 50
w
W
K
10
D
50
J
90
0 2 4
FIGURE 6 Progressive release of [14C]serotonin
(F- E), ß-glucuronidase (ß-GLUC) (0-0),
and lactic dehydrogenase (LDH) (o- (D) after
stirring PRP in an aggregometer with 1 .0 µM phorbol
ester. Less than 11% of the [19C]serotonin, 35% of the
ß-glucuronidase and 20% of the lactic dehydrogenase
present in frozen and thawed PRP was found in the su-
pernatant of control samples stirred without phorbol
ester, and these values did not change during 120 min
incubation.
the aggregometer either with a concentration of
phorbol ester too low to cause a second phase of
aggregation within the 7-10 min of observation,
or with a low concentration in the presence of
apyrase or CP plus CPK. Phentolamine (0.05
mg/ml) and ouabain (10 µM), incubated 10
min had no effect. Adenosine (0.1 mM incubated
for 30 s), 0 .14 µM PGE1, and 0.5 mM N-ethyl-
maleimide (both incubated for 5 min) virtually
abolished aggregation. Metabolic inhibitors were
incubated with PRP for 30 min before adding CP
plus CPK and phorbol ester. Sodium cyanide
(2 mM) and 2-deoxyglucose (9 mM) had no
8
	
10
	
12
	
14
	
16
	
18
MINUTES
FIGURE 5 Aggregometer tracings of [14C]serotonin-labeled PRP stirred with isotonic saline (top line)
or 0.03 AM phorbol ester in a large cuvette (Chrono-log aggregometer) . At intervals, samples were re-
moved and the plasma analyzed for 14C (given in percent of total) and ADP and ATP (combined mi-
cromolar value given). A small number of residual platelets accounts for the nucleotides in the control
plasma. LTU, light transmission units.
6
effect alone but together prevented aggregation .
Aspirin (0.1 mM, incubated for at least 5 min)
did not inhibit the effect of these low phorbol ester
concentrations, inhibited the steep phase of aggre-
gation with slightly higher levels, and had no
effect on aggregation with high (e.g., 0.5 MM)
levels. Its effect thus resembled that of ADP-
destroying enzymes. Usually, there was no addi-
tive effect when the enzymes and aspirin were
both present. When aggregation was associated
with appreciable release of [14C]serotonin and was
inhibited by aspirin, release of radioactivity was
usually also reduced.
Experiments with Washed Platelets
Washed platelets were more sensitive to phorbol
ester than platelets in PRP . Thus, even 0.001 µM
phorbol ester released 12% [14C]serotonin and
caused a sigmoidal aggregation curve ; these ob-
servations strongly suggested that ADP had been
released. A sigmoidal curve and over 20% [14C]
serotonin release were observed with 0 .01 µM
phorbol ester in the presence of CP plus CPK, or
with PRP from a donor who had recently in-
gested aspirin. When these inhibitors were added
together, 0.01 µM released negligible radioactiv-
ity, and aggregation proceeded in a linear fashion,
suggesting that released ADP did not play a part .
Frozen and thawed washed platelets at a con-
centration of 106/µl caused a moderate inflam-
matory response as judged from the size and color
of the local accumulation of Evans blue dye in
rabbit skin. No greater response was noted with
twice as many platelets, and a lesser response
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331TABLE III
The E ffect of Inhibitors on Aggregation Induced by Phorbol Ester or ADP after 4 Min Shaking
* Degree of aggregation without inhibitor was always 4+ .
TABLE IV
E ffect of Phorbol Ester and PGEI on Platelet
Cyclic AMP
PRP with :
Cyclic AMP
PGEI
	
Phorbol ester
µM
	
µM
	
pmot/l09 platelets
Material stirred
0
	
0
	
140
	
with platelets
0 3.0 148
0.3 0 250
0.3 0.3 226
0.3 1 .0 218
0.3
	
3 .0
	
198
1.6 ml PRP was incubated alone or with PGEI for
5 min. It was then stirred with or without phorbol
ester for 3 min, and an equal volume of 12% tri-
chloracetie acid was added.
or none with 500,000 platelets/µl . 1 µM phorbol
ester alone had little or no inflammatory effect.
When platelets at a concentration of 2 X 10 6/µl
were stirred for 30 min with 1 µM phorbol ester
and the mixture was centrifuged, the super-
natant had a moderate inflammatory effect.
There was a negligible response to the super-
natant of the control 30 min sample without
phorbol ester or of a sample stirred for only 5
min with phorbol ester (Table V) . As noted
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TABLE V
Release of Inflammatory Activity from Washed
Platelets by Phorbol Ester (PhE)
1 :1,000 DMSO
1 :1,000 DMSO,
AM PhE
1 :1,000 DMSO
1 :1,000 DMSO,
µM PhE
0.45 ml platelet suspension (2 X 106/µl) was stirred
at 37°C with 0.05 ml 1 :100 DMSO with or without
10 µM phorbol ester for 5 or 30 min. A second set
was made with [ 14C]serotonin-labeled platelets,
and all of the mixtures were centrifuged in a
Serofuge (Clay Adams, Div . Becton, Dickinson
and Co., Parsippany, N. J .) for 10 min. The super-
natants of the unlabeled platelets were tested for
their inflammatory effect, radioactivity was meas-
ured in the supernatants of the labeled set, and
supernatants of both sets were combined and
frozen for subsequent determination of ,ß-glucu-
ronidase.
Inhibitor Phorbol ester ADP
Concentration Incubation Concentration Aggregation* Concentration Aggregation*
mm min µM µM
PGEI 0 .0003 5 2 .7 3+ 1 .0 0
PGE1 0 .0003 5 0 .3 1+ 3 .0 0
PGEI 0 .003 5 0.95 2+ 12 .5 0
PGE2, PGF1a , PGF2a 0 .003 5 0.95 4+ 12 .5 2+
Theophylline 2 5 0 .3 2+ 5 0
Dibutyryl cyclic AMP 5 5 0 .3 2+ 5 0
Theophylline + dibutyryl 2 + 5 5 0 .3 0 5 0
cAMP
N-Ethylmaleimide 5 0 .67 0 1 .0 0 0 .5
Iodoacetate 0 .5 30 0 .67 2+ 1 .25 2+
Sodium cyanide 2 30 0 .67 4+ 1 .25 4+
Iodoacetate + cyanide 0 .5 + 2 30 0 .67 0 1 .25 0
L-TLCK 0 .1 5 2 .7 4+ 10 4+
L-TLCK 1 .0 5 2.7 0 10 1+
L-TPCK 0 .15 15 5 4+ 10 0
L-TPCK 0 .30 15 5 2+ 10 0
Duration
of
stirring
Supernatant
Inflam-
matory
response
[I4C]sero-
tonin
(% of
total)
ß-glu-
curoni-
dase
(% of
total)
min
5 f 4 5 .3
1 5 t 43 2 .5
30 Neg 3 3 .8
1 30 2+ 41 12 .5earlier (Fig. 6) ß-glucuronidase was released
only after the longer period of stirring.
DISCUSSION
Interest in phorbol ester stems from its activity
as a tumor-promoting agent. Mice whose skin
has been prepared by an application of 7, 12-
dimethylbenz(a)anthracene begin to develop
tumors in 6 wk when phorbol ester is applied
three times weekly in a concentration of 0 .1-1 .0
µg per 10 µl of solvent (16-160 µM) (1, 2, 23) .
Croton oil or phorbol ester stimulates mitoses
(24) and DNA (25, 26) and RNA (27) synthesis
in mouse skin. In stationary cultures of 3T3
fibroblasts, phorbol ester causes RNA synthesis,
removes density-dependent inhibition of cell
division (28), and induces a change in cell re-
fractility (29). The ester binds to cell membranes
in a form which is removed by methanol (30)
and, in very low concentrations, enhances the
incorporation of choline into lecithin in cultured
cells (31) and of phosphate into lecithin in mouse
skin (32) . It also causes an immediate fourfold
increase in the activity of Na-K-dependent ATPase
when added to isolated cell membranes in a
concentration of 3 .2 AM. The activity of 5'-
nucleotidase in the membrane is increased 70 %,
but there is no effect on NADH diaphorase or
glucose-6-phosphatase (33).
Although the tumor-promoting potential of
phorbol ester was thought to be related to its
lytic effect on lysosomes (34), skin lysosomes have
proved relatively resistant (29) and attention is
now focused on its effects on cell membranes and
the mechanisms by which these effects are trans-
mitted to the cell interior. Application of 10 µM
phorbol ester to mouse skin resulted in a rapid fall
in cyclic AMP. The minimum level was reached
in 2 h, and the value did not return to normal for
48 h. Dibutyryl cyclic AMP plus theophylline
markedly inhibited phorbol ester's potential for
inducing tumors (35) and epidermal mitoses
(Belman and Troll, unpublished observations) .
These results are significant in relation to the fall
in cyclic AMP associated with mitosis (36).
The possible role of proteases in the action of
phorbol ester is suggested by the fact that local
application of L-TPCK inhibits tumor develop-
ment (37) .
Our observation that low concentrations of
phorbol ester cause platelet aggregation provides
new evidence for the interaction of this substance
with cell membranes. Phorbol ester is active at 0 .02
µM with PRP, and at 1 nM with washed plate-
lets, making it the most active platelet-aggregating
agent known.
Released ADP plays an important role in the
aggregation produced by intermediate concen-
trations of phorbol ester. ADP and ATP were
found in the supernatant plasma 10 min after
aggregation was induced by at least 0.05 µM
phorbol ester. Furthermore, at concentrations
between 0.03 and 0.1 µM, aggregation was
markedly inhibited by enzymes which destroy
ADP. The change in platelet shape caused by all
but low concentrations of phorbol ester is pre-
sumably due to released ADP. As with ADP
(38, 39), the change occurs in thrombasthenia or
when aggregation is prevented by EDTA .
Released ADP does not appear to be important
in aggregation induced by low concentrations of
phorbol ester. No released ADP could be de-
tected after 10 min, and slow progressive aggre-
gation occurred even in the presence of CP plus
CPK or apyrase. The failure of these enzymes
to inhibit the effect of low concentrations of
phorbol ester while inhibiting much of the effect
of somewhat higher concentrations indicates
that phorbol ester has a primary effect on platelets
for which released ADP cannot be responsible .
This primary effect was not associated with a
change in platelet shape and was not inhibited by
aspirin, ouabain, or phentolamine .
The effect of high concentrations of phorbol
ester (i.e., over 0.1 AM) is also probably not
mediated by released ADP since the slight inhibi-
tion of aggregation caused by apyrase or CP plus
CPK is not increased by increasing the concen-
tration of these ADP-destroying enzymes to levels
which prevent the effect of 50 µM ADP-con-
siderably more than could be released by the
platelets in PRP. However, the possibility cannot
be ruled out that released ADP exerts its effect
as it leaves the platelet, before it is accessible to
the added enzymes.
Inhibitors of ADP-induced aggregation are
effective at all levels of phorbol ester. Aggregation
induced by ADP and by low and intermediate
concentrations of phorbol ester is abolished by
chelating calcium ions with EDTA or EGTA and
is absent in PRP from patients with thrombas-
thenia (38, 40) . High concentrations (e.g., 0.5
µM phorbol ester) have a slight effect under these
conditions.
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333The effect of other inhibitors on the primary
effect of low phorbol ester concentrations was
tested in the presence of CP plus CPK to eliminate
any effect of released ADP. Aggregation under
these conditions was markedly inhibited by adeno-
sine, PGE 1, N-ethylmaleimide, and metabolic
poisons. These inhibitors, as well as others, were
also effective against intermediate and high
concentrations of phorbol ester (Table III) . As
with ADP (8, 9, 41), aggregation induced by
high concentrations of phorbol ester is inhibited by
dibutyryl cyclic AMP and substances which
raise cyclic AMP such as theophylline and PGE1 .
As with ADP (41), phorbol ester lowers the cyclic
AMP concentration of platelets when it has been
elevated by exposure to PGE 1. Aggregation by
both ADP (7, 8, 9, 10) and phorbol ester is
inhibited by the sulfhydryl inhibitor N-ethyl-
maleimide, by the protease inhibitors L-TLCK
and L-TPCK, and by inhibition of glycolysis,
especially when respiration is also blocked .
Platelets contain a high concentration of con-
tractile protein (i.e., platelet actomyosin ; throm-
bosthenin) which is involved in clot retraction
and perhaps also in aggregation and the release
reaction (11, 12, 13, 42) . At least some of this
protein is localized at the cell surface (40, 43, 44),
and is presumably responsible for the ouabain-
insensitive ecto-ATPase activity of platelets (12) .
Because actomyosin has been implicated in platelet
aggregation, Puszkin and Zucker (45) tested the
effect of phorbol ester on actomyosin isolated from
platelets and skeletal muscle. It was found to
stimulate ATPase activity and enhance superpre-
cipitation at very low concentrations . Higher con-
centrations inhibited superprecipitation. Further-
more, phorbol ester, like ADP, caused retraction
of fibrin clots produced by the enzyme Reptilase.
Unlike clots produced by thrombin, those pro-
duced by Reptilase do not retract in the absence
of phorbol ester or ADP . Evidence was provided
that released ADP was not responsible for most of
the clot-retracting effect of phorbol ester (45) .
These findings suggest that the primary aggre-
gating effect of phorbol ester is mediated by
platelet actomyosin. Recent studies have shown
that added ADP enhances superprecipitation (46)
and that ADP derived from ATP by the ATPase
action of actomyosin seems essential for superpre-
cipitation (45), additional evidence for the role
of actomyosin in ADP-induced aggregation as
well. Interference with the level of ionized cal-
334
	
THE JOURNAL OF CELL BIOLOGY . VOLUME 60, 1974
cium, energy metabolism, sulfhydryl groups,
and cyclic AMP levels could thus inhibit both
primary ADP- and phorbol ester-induced aggrega-
tion because they affect the contractile mechanism .
This unified theory is supported by the observa-
tions that ADP and phorbol ester cause platelets
to retract Reptilase-induced clots and that plate-
lets of patients with thrombasthenia fail to promote
clot retraction (38) and do not aggregate with
ADP and only slightly with high concentrations
of phorbol ester.
It is of interest that both ADP and phorbol
ester accelerate phospholipid synthesis ; ADP
augments the incorporation of 32P into phospha-
tidic acid and di- and triphosphatidyl inositol
within 30 s (47) and, in other cells, phorbol ester
enhances incorporation of choline and phosphate
into lecithin (31, 32) .
Release induced by phorbol ester has features
in common with the platelet release reaction
caused by ADP, epinephrine, and collagen (6-10) .
Aspirin, a known inhibitor of the release reaction
(6, 9, 10), inhibited the steep phase of aggregation
induced by low concentrations of the tumor
promoter. When aggregation was associated with
release of [19C]serotonin, aspirin usually reduced
the amount of radioactivity released . As with
other agents which induce the release reaction
(6), the rapid early release of [14C]serotonin and
nucleotides caused by 1 µM phorbol ester was
not accompanied by release of ß-glucuronidase, an
enzyme found in alpha granules, or of lactic
dehydrogenase, a cytoplasmic enzyme. ADP
enhanced phorbol ester-induced release, as shown
by the diminished release of [14C] serotonin in the
presence of ADP-destroying enzymes. A similar
effect has been shown for other releasing agents
(22) . On the other hand, the release of [14C]sero-
tonin induced by 1 µM phorbol ester differed
from that caused by ADP (7), since it was not
inhibited'-by EDTA and occurred in thrombas-
thenia. Furthermore, ß-glucuronidase and lactic
dehydrogenase were liberated when stirring was
continued for longer periods . Liberation of these
enzymes was apparently not simply due to lysis,
since there was much less release when aggrega-
tion was prevented by calcium chelation or lack
of stirring. White et al. (48) also observed that
phorbol ester causes release and degranulation .
The unusual characteristics of release are in
harmony with their electron microscope studies
showing that degranulation is associated with atype of granule swelling which does not occur
during a typical release reaction. Dissimilarities
between the release reaction induced by phor-
bol ester and other aggregating agents led us
to the earlier erroneous conclusion that it did not
induce release (49).
Inflammatory activity was released with /3-glu-
curonidase when washed platelets were incubated
for 30 min with phorbol ester, and can probably
be attributed to a cationic protein with inflam-
matory properties which has been isolated from
human platelets (20). Because human plasma
itself caused inflammation, experiments could not
be carried out on PRP, but it seems likely that
in plasma, release of inflammatory material from
platelets would also accompany the release of
/3-glucuronidase. However, the role of platelets
in the inflammatory reaction to phorbol ester
remains to be established, since platelet aggregates
were not noted in histologic sections of the ears
of mice prepared 30 min to 24 h after application
of inflammatory concentrations of phorbol ester
(50) . Whether or not platelets prove to be related
to phorbol ester's inflammatory and tumor-
promoting activity, their rapid and profound
response to low concentrations of this compound
provides a new means of investigating its action
on cells as well as the general mechanism of cell
aggregation.
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